Clinical Trials
6
Active:0
Completed:2
Trial Phases
3 Phases
Early Phase 1:1
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (50.0%)Early Phase 1
1 (25.0%)Phase 1
1 (25.0%)A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Phase 2
- Conditions
- Pulmonary HypertensionPulmonary Fibrosis
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Bellerophon
- Target Recruit Count
- 85
- Registration Number
- NCT05747508
- Locations
- 🇺🇸
Arizona Pulmonary Specialists, Phoenix, Arizona, United States
🇺🇸University of California, Los Angeles, California, United States
🇺🇸University of California Davis Health, Sacramento, California, United States
Expanded Access for Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis
- Conditions
- Pulmonary FibrosisPulmonary Hypertension
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Bellerophon
- Registration Number
- NCT05356052
Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19
- Conditions
- Coronavirus InfectionCOVID-19Pneumonia, Viral
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Bellerophon
- Registration Number
- NCT04358588
A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis
Phase 2
Completed
- Conditions
- Pulmonary HypertensionSarcoidosis, PulmonaryPulmonary Fibrosis
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Bellerophon
- Target Recruit Count
- 17
- Registration Number
- NCT03727451
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Temple University, Philadelphia, Pennsylvania, United States
Effect iNO on Functional Respiratory Imaging in Subjects With WHO Group 3 Pulmonary Hypertension With COPD on Oxygen
Early Phase 1
Terminated
- Conditions
- COPDChronic Obstructive Pulmonary DiseasePulmonary Hypertension
- Interventions
- Drug: Inhaled Nitric Oxide 30mcg/kg IBW/hr
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Bellerophon
- Target Recruit Count
- 7
- Registration Number
- NCT03135860
- Locations
- 🇧🇪
Antwerp University Hospital, Edegem, Belgium
- Prev
- 1
- 2
- Next
News
No news found